Foresee Pharmaceuticals Enters Exclusive License Agreement with Accord Healthcare

TAIPEI, Taiwan, Feb. 11, 2019 -- (Healthcare Sales & Marketing Network) -- An exclusive license agreement for the commercialisation of Foresee Pharmaceutical's (6576.TWO) novel FP-001 program (leuprorelin depot), Leuprolide Mesylate Injectable Suspension ... Biopharmaceuticals, Licensing Foresee Pharmaceuticals, Accord Healthcare, leuprorelin
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news